Clinical trial
Evaluate the Efficacy and Safety of ACTIQ in Patients With Cancer and…
NCT00236145 · Cephalon, Industry · Completed
Key facts
| NCT number | NCT00236145 |
|---|---|
| Title | Evaluate the Efficacy and Safety of ACTIQ in Patients With Cancer and Breakthrough Pain |
| Official title | A Randomised, Open-label, Parallel-group Study to Evaluate the Efficacy and Safety of ACTIQ (Oral Transmucosal Fentanyl Citrate) Titrated According to 2 Regimens in Patients With Cancer and Breakthrough Pain |
| Lead sponsor | Cephalon, Industry |
| Status | Completed |
| Phase | Phase 3 |
| Study type | Interventional |
| Conditions | Breakthrough Pain |
| Intervention type | Drug |
| Interventions | ACTIQ (Oral transmucosal fentanyl citrate) |
| Start date | Jun 1, 2004 |
| Primary completion | Aug 1, 2005 |
| First posted | Oct 12, 2005 |
| Last update posted | Jan 29, 2013 |
At a glance
- No Results posted
- None Linked FDA submissions
Counts are shown as ranges. Exact figures, trends and every underlying record are available in Orca1.
About ClinicalTrials.gov studies
ClinicalTrials.gov is the U.S. National Library of Medicine's registry of clinical studies conducted around the world. Contact and investigator details are not shown here.
Source: U.S. National Library of Medicine (NLM), ClinicalTrials.gov · Source date: